Alberta Health Services	Tetanus-Diphtheria Combined Vaccine Biological Page	
Section 7:	**Biological Product Information**	**Standard #: 07.320**
Created by:	Province-wide Immunization Program Standards and Quality	
Approved by:	Province-wide Immunization Program Standards and Quality	
Approval Date:	January 27, 2012	**Revised:** January 1, 2021

	Td Adsorbed®
Manufacturer	Sanofi Pasteur Limited
Biological Classification	Inactivated
Indications for Provincially Funded Vaccine	• Primary or reinforcing immunization of individuals 18 years of age and older. • Individuals who sustain a tetanus prone wound need to have their tetanus immunization history assessed. See Tetanus Prevention, Prophylaxis and Wound/Injury Management Standard # 08.400. **Notes:** • Td may be administered as an alternative to dTap OR when dTap is not available OR the pertussis component is contraindicated. • To determine tetanus-diphtheria containing vaccine of choice for HSCT/SOT individuals, refer to Transplant Guidelines #08.304.
Schedule	**Primary Vaccine Series:** • Dose 1 – day 0 • Dose 2 – 4 to 8 weeks after dose 1 • Dose 3 – 6 to 12 months after dose 2 **Reinforcing Doses:** • Reinforcing doses are recommended at 10-year intervals. • dTap is used for routine adult immunization. • For wound management purposes, shorter intervals may be recommended (Tetanus Prevention, Prophylaxis and Wound/Injury Management Standard # 08.400).
Serology	**Pre-Immunization & Post-Immunization** • Serological testing is not typically recommended to assess levels of immunity to diphtheria or tetanus. For additional information see the AH DAT/TAT Interpretation tables https://open.alberta.ca/publications/aefi-policy-for-alberta-immunization-providers
Preferred Use	N/A
Dose	0.5 mL
Route	IM
Contraindications/ Precautions	**Contraindications:** • Known severe hypersensitivity to any component of the vaccine. • Anaphylactic or other allergic reaction to a previous dose of vaccine containing tetanus and diphtheria toxoids.

	Td Adsorbed®
	Precautions: • If Guillain-Barré Syndrome (GBS) occurred within 6 weeks of immunization with a previous dose of vaccine containing tetanus toxoid, it is prudent to withhold subsequent doses of tetanus-containing vaccine. Those who develop GBS outside this interval or have an alternative cause identified may receive subsequent doses of tetanus-containing vaccine. • Frequent booster doses of tetanus and diphtheria toxoids may lead to severe local and systemic reactions and may be associated with high levels of circulating antitoxin.
Possible Reactions	**Common:** • Pain, redness and swelling at injection site • Fever, chills • Sore or swollen joints • Drowsiness **Rare:** • Anaphylaxis • Arthus-type injection site reaction • Persistent nodule at the site of injection • As with any immunization, unexpected or unusual side effects can occur. Refer to the product monograph for more detailed information.
Pregnancy	Adequate data is not available for the use of Td vaccine during pregnancy and therefore will not routinely be recommended in Alberta for pregnant women. However, use of this vaccine during pregnancy may be considered in consultation with your MOH based on the individual's risk of disease versus benefit of the vaccine.
Lactation	Td vaccine can be administered to eligible breastfeeding women.
Composition	Each 0.5 mL dose contains: **Active Ingredients:** • Tetanus toxoid - 5 Lf • Diphtheria toxoid - 2 Lf **Non-medical Ingredients:** • **Excipients:** o Aluminum phosphate (adjuvant) - 1.5 mg o 2-phenoxyethanol - 0.6% v/v o Isotonic solution of sodium chloride in water for injection - q.s. 0.5 mL • **Manufacturing residuals:** Trace amounts of: o Formaldehyde
Blood/Blood Products	Does not contain human blood or blood products.
Bovine/Porcine Products	• Bovine-derived products may be present in small amounts either as components of the culture media used to manufacture the vaccine or as a component of the final vaccine. • Porcine-derived products are used as raw materials in the early stages of the manufacturing process.
Latex	The container closure system is free of latex (natural rubber).
Interchangeability	Individuals who begin their immunization with a different combined product may complete immunization using Td as appropriate for age.

	Td Adsorbed®
Administration with Other Products	• May be given at the same time as other inactivated vaccine using a separate needle and syringe for each vaccine. • The same limb may be used if necessary, but different sites on the limb must be chosen.
Appearance	Uniform cloudy suspension.
Storage:	• Store at $+2^0$C to $+8^0$C • Do not freeze • Do not use beyond the labeled expiry date • Store in original packaging when possible to protect from light
Vaccine Code	Td
Antigen Code	Tetanus – T Diphtheria – D
Licensed for	Individuals 7 years of age and older.

Notes:

- 1980: The combined Td vaccine was introduced into the Alberta Provincial program.
- 2021 January 1: dTap replaced Td for routine Adult immunization.

Related Resources:

- Tetanus and Diphtheria Information Sheet (104509)

References:

1. Alberta Health. (2019, April 1). Alberta Immunization Policy. *Adverse Event Following Immunization (AEFI) Policy for Alberta Health Services Public Health*.
2. Alberta Immunization Policy. Biological Products . (2020, December). *Tetanus and Diphtheria Combined Vaccine.*
3. National Advisory Committee on Immunization. Canadian Immunization Guide (Evergreen Edition). Ottawa, ON: Public Health Agency of Canada. https://www.canada.ca/en/public-health/services/canadian-immunization-guide.html.
4. Sanofi Pasteur Limited. (2012, October). Product Monograph. *Td ADSORBED: Tetanus and Diphtheria Toxoids Adsorbed*.